This free script provided by
JavaScript Kit

Tamoxifen citrate

Catalog #:

IN0073-1g USD118.0

References for Tamoxifen:

1. Phuong, N. T., Kim, S. K., Lim, S. C., Kim, H. S., Kim, T. H., Lee, K. Y., Ahn, S. G., Yoon, J. H., and Kang, K. W. Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells. Breast Cancer Res Treat, 130: 73-83.

2. Criscitiello, C., Fumagalli, D., Saini, K. S., and Loi, S. Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection. Onco Targets Ther, 4: 1-11.

3. Abo-Touk, N. A., Sakr, H. A., and Abd El-Lattef, A. Switching to letrozole versus continued tamoxifen therapy in treatment of postmenopausal women with early breast cancer. J Egypt Natl Canc Inst, 22: 79-85.

4. Aihara, T., Suemasu, K., Takei, H., Hozumi, Y., Takehara, M., Saito, T., Ohsumi, S., Masuda, N., and Ohashi, Y. Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy. Oncology, 79: 376-381.

5. Stendahl, M., Nilsson, S., Wigerup, C., Jirstrom, K., Jonsson, P. E., Stal, O., and Landberg, G. p27Kip1 is a predictive factor for tamoxifen treatment response but not a prognostic marker in premenopausal breast cancer patients. Int J Cancer, 127: 2851-2858.

6. Gao, L., Tu, Y., Wegman, P., Wingren, S., and Eriksson, L. A. Conformational enantiomerization and estrogen receptor alpha binding of anti-cancer drug tamoxifen and its derivatives. J Chem Inf Model, 51: 306-314.

Certificate of Analysis/MSDS is available upon request with lot number

Home | Contact | Support | Privacy Policy, Terms Warranty | Apycom jQuery Menus